While simple steatosis may be clinically stable, nonalcoholic steatohepatitis (NASH) can be progressive. Inflammation is believed to be the driving force behind NASH and the progression to ...

Liver biopsy and noninvasive markers should be used to stage and grade nonalcoholic steatohepatitis (NASH) in patients ... in reducing the NAFLD-induced inflammation and improving cellular ...

Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

Gilead's top late-stage drug selonsertib ... be announced later this year. NASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver, which ...

The therapy inhibits the inflammation that turns an ... mortality rate in these patients is high. NASH is less deadly, particularly in its early stages, but affects a large and growing number ...

Novartis has added another non-alcoholic steatohepatitis (NASH) drug candidate to its pipeline ... The agreement focuses on PLN-1474, a preclinical-stage drug that works as a small-molecule ...

These organizations can help you educate yourself, spread awareness, and connect with the MASH community to help you better ...

NASH is a complex liver disease marked by too much fat buildup in liver cells and inflammation. To create precise treatments, it is crucial to fully grasp how NASH-related biomarkers work in both ...

Of those with NAFLD, about 20 percent have NASH, which occurs when there is inflammation and liver cell ... the FDA limited the drug to those with stages 2 and 3 fibrosis, but did not specify ...

NASH is a serious form of liver disease characterized by excess fat buildup and inflammation in the liver ... take it by mouth each day. In a late-stage study published last month, Rezdiffra ...

Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology ... nonalcoholic steatohepatitis (NASH), is characterized by dysregulated metabolism, inflammation and fibrosis. According to Axcella ...